Lundbeck’s Migraine Prevention Treatment Sees Phase Two Success

Lundbeck reported that its IV anti-PACAP antibody met the main goal in the phase 2b Proceed trial. In 431 patients who had not responded to prior preventive treatments, multiple IV doses significantly reduced monthly migraine days over 12 weeks compared to placebo. The drug was generally well tolerated, and the company plans to discuss phase 3 development with regulators.